3 Buffett-Like Ways to Double Your Money in 2020

Hunting for a bargain? This group of beaten-down stocks, including Aurora Cannabis (TSX:ACB)(NYSE:ACB), might provide the value you’re looking for.

| More on:
Money growing in soil , Business success concept.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Hi there, Fools. I’m back to call attention to three stocks at new 52-week lows. Why? Because the big gains in the stock market are made by buying attractive companies

As legendary value investor Warren Buffett once quipped, “Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.”

So, if you’re looking to double your money in 2020, this is a good place to start your search.

Pot shots

Leading off our list is cannabis producer Aurora Cannabis (TSX:ACB)(NYSE:ACB), which is down a whopping 66% over the past year and currently trades at 52-week lows of $2.39 per share.

Rising costs, disappointing revenue growth, and concerns over a shaky balance sheet continue to weigh heavily on the stock. And most recently, Aurora’s chief corporate officer Cam Battley, one of the company’s most important executives, decided to step down.

On the positive side, Aurora remains a market share leader in the space, providing contrarian Fools with a possible long-term opportunity.

“Despite short term distribution and regulatory headwinds in Canada that have temporarily impacted the industry, the long-term opportunity for Aurora in the global cannabis and cannabinoids market is immense,” said CEO Terry Booth in November.

Aurora currently sports a beta of 1.6.

Important information

Next up, we have information management specialist Information Services (TSX:ISV), whose shares are off about 6% over the past six months and currently trade at 52-week lows of $15.19.

The stock has been pressured by lacklustre revenue growth over the past year, but now might be a prime opportunity to pounce. In the most recent quarter, for example, free cash flow remained strong at $6.6 million, as revenue improved to $32 million.

More importantly, the company remains on track to meet its full-year 2019 guidance.

“Our performance in the third quarter was as expected and we remain a strong free cash flow business,” said CEO Jeff Stusek. “Registry Operations continues to be challenged by the effects of economic conditions but is delivering robust results.”

Information Services currently offers a fat dividend yield of 5.2%.

Playing the organ

Rounding out our list is cannabis products specialist OrganiGram Holdings (TSX:OGI)(NASDAQ:OGI), which is down more than 50% over the past year and currently trades at 52-week lows of $2.64 per share.

Hurdles in the Canadian legal market for edibles, near-term uncertainty, and general industry concerns have weighed on the stock. But with that said, OrganiGram might now be too cheap to pass on.

In the most recent quarter, the company’s revenue popped 547%. More importantly, OrganiGram’s balance sheet remains relatively conservative.

“We have great conviction in our strategy and ability to onboard the new retail store openings and to launch a portfolio of edible and derivative products appealing to adult consumers,” said CEO Greg Engel. ”

OrganiGram shares trade at a forward P/E in he high teens.

The bottom line

There you have it, Fools: three ice-cold stocks worth checking out.

As always, don’t see them as formal recommendations. Instead, view them as a starting point for more research. Trying to catch a falling knife can be hazardous to your wealth, so plenty of homework is still required.

Fool on.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool recommends OrganiGram Holdings and OrganiGram Holdings.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »